Navigation Links
Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Date:5/11/2009

of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended March 31, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


                                  PHARMASSET, INC.
            CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE NET LOSS
                                     (UNAUDITED)

                           Three Months Ended           Six Months Ended
                               March 31,                   March 31,
                               ---------                   ---------
                           2009          2008          2009          2008
                           ----          ----          ----          ----

    REVENUES            $1,902,679      $464,292    $2,366,970      $928,583
                        ----------      --------    ----------      --------

    COSTS AND EXPENSES:
      Research and
       development      13,694,247     8,990,469    27,717,177    19,540,840
      General and
       administrative    2,893,504     3,809,073     6,962,874     6,428,818
                         ---------     
'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset Receives $10 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, will ... Align Technology, on “ Conducting Postmarket Registries - Rationale ... Conference and Exhibition on April 25th through April 28th ... poster presentation, Ale Gicqueau and Victor Chen will discuss ... the requirements and resources to conduct the registry, as ...
(Date:3/25/2015)... March 26, 2015 Agnition announced today ... of American Farmer, airing for the first time at ... of American Farmer will explore the extremely important role ... producers with a patented Microbial Catalyst™ technology that enhances ... yields. The segment will air again on April 28. ...
(Date:3/25/2015)... The surging prevalence of internet use ... media growth, with over 50% of the world’s ... Insurance companies are making use of social media ... a diversity of their services and products. , ... networking services as part of sales and marketing, ...
(Date:3/25/2015)... -- Accelovance, a therapeutically focused contract research organization (CRO), ... Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards ... This is the eighth consecutive year Accelovance has been ... "Best Contract Research Organization" in 2009, 2010, and 2011, ... "We,re excited to be a finalist for the ...
Breaking Biology Technology:Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2
... The Netherlands, December 22 Dosage,recommendations for newborns being cared ... likely be based on more individual characteristics than,just body weight. ... Dutch Top,Institute Pharma in which Leiden University (Prof M. Danhof) ... represented. , Catherijne Knibbe, clinical pharmacologist ...
... Fla., Dec. 21 , www.bioheartinc.com , ... , A large quantity of stem cells can be obtained ... effects, quickly and cheaply. Adipose stem cells are capable of ... blood vessels. Lower limb ischemia is pain, often severe enough ...
... , , ANNAPOLIS, Md., Dec. 21 ... company developing medical countermeasures against biological and chemical threats, today ... Board of Directors, increasing the Board to eight members. ... a firm providing advisory services in business risk management, homeland ...
Cached Biology Technology:Research: Dosage of Morphine for ill Newborns Still too Imprecise 2Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue 2Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue 3Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue 4Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue 5PharmAthene Appoints Jeffrey W. Runge, M.D. to the Company's Board of Directors 2PharmAthene Appoints Jeffrey W. Runge, M.D. to the Company's Board of Directors 3
(Date:3/20/2015)... OXFORD, Conn. , March 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... Wocket® smart wallet is one of the products featured ... today, March 20th at 11:00 PM EST on the ... travels to Las Vegas , site ...
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... MINNETONKA, Minn. , March 17, 2015 /PRNewswire/ ... sciences technology company specializing in clinical study management ... will be in attendance at ARENA,s Outsourcing in ... Cary, NC.  This event provides an excellent forum ... company,s easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... Safety System Equip Officers with Access to Mobile ... 6 BIO-key International, Inc. (OTC ... identification and wireless public safety solutions and its ... of Public Safety Software, announced nine recent mobile ...
... Johns Hopkins has convinced an international group of colleagues ... and instead begin a 7,000-hour slog through a compendium ... and analyze the molecules that might herald the furtive ... available for the exhaustive and expensive testing that needs ...
... 2009) Cell Press, an imprint of Elsevier, announced today ... Current Biology and The American Journal of ... (SLA) Top 100 Journals in Biology and Medicine of the ... the 680-plus members of the SLA,s Biomedical and Life Sciences ...
Cached Biology News:Nine Additional Virginia Law Enforcement Agencies Deploy BIO-key(R) and DaPro Systems Solution 2Nine Additional Virginia Law Enforcement Agencies Deploy BIO-key(R) and DaPro Systems Solution 3Nine Additional Virginia Law Enforcement Agencies Deploy BIO-key(R) and DaPro Systems Solution 4Compendium of pancreatic cancer biomarkers established as strategic approach to early-detection 2Compendium of pancreatic cancer biomarkers established as strategic approach to early-detection 33 prominent Cell Press journals named among the 100 most influential journals in past 100 years 2
... with 5.6" TFT color screen, without Camera ... digital camera with 8.0 mega pixel resolution. It ... small budget. View image from large 5.6" TFT ... It is suitable to capture image for fluorescent ...
...
... conserved form of cell suicide, which follows ... component of this process is a cascade ... enzymes participate in a series of reactions ... signals and result in the cleavage of ...
... derivative for high-yield protein expression ... from a high-yielding clone of Sf9 cells. ... Insect Cell Medium, these cells are recommended ... either baculovirus infection or transfection of appropriate ...
Biology Products: